- ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D
This early-stage study is for people with type 2 diabetes. It's looking at how a new medicine, NEX-22A, moves through the body. The main goal is to understand how the body handles this new treatment.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
PIONEER TEENS Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes.
This study is looking at a medicine called Rybelsus for teenagers with type 2 diabetes. It wants to see if Rybelsus, taken with other common diabetes medicines, helps control blood sugar and is safe. The study compares Rybelsus to a dummy pill to understand its effects better.
Greece · Czechia · Portugal - enrolling by invitation
PDE3B in Metabolic Regulation
This study looks at how a protein called PDE3B affects how our bodies handle sugar and fat. Researchers want to understand if changes in this protein could protect people from conditions like type 2 diabetes and heart disease, potentially leading to new treatments.
United Kingdom - active not recruiting
Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes
This study looks at how Type 2 diabetes affects important organs like your kidneys, liver, and heart. We're using special MRI scans to find out who might be at risk of complications, helping us understand and manage diabetes better for people in the UK.
United Kingdom - recruiting
Capillary OGTT Study
This study is looking for new, easier ways to test for diabetes (Type 1 and Type 2) in children and young people. Instead of tricky hospital blood tests, we want to see if finger-prick tests at home or skin sensors can give reliable results.
United Kingdom - recruitingNA
Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes
This study looks at how using a special glucose monitor (Dexcom ONE) might help people with type 2 diabetes manage their blood sugar after a heart attack. It aims to see if better blood sugar control improves health over six months.
United Kingdom - active not recruiting
Multi-morbidity Screening in People With Type 2 Diabetes and Pre Diabetes
This study checks for other health issues often linked with Type 2 diabetes and pre-diabetes, like problems with your heart, liver, or sleep. It's testing a new, more thorough health check-up to find these problems earlier.
United Kingdom - recruitingNA
Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study
This study looks at how a special low-energy diet helps teenagers with obesity and type 2 diabetes. It aims to see if they can lose enough weight to reverse their diabetes and how easy it is for them to stick with the diet.
United Kingdom - recruitingPHASE3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
This study looks at a new medicine for adults with overweight or obesity and type 2 diabetes. It aims to see if the medicine helps with weight loss and is safe. The medicine is given as a weekly injection under the skin.
United States · Argentina · Bulgaria - recruitingNA
Gut Hormones and Roux en Y Gastric Bypass
This study looks at how weight-loss surgery (gastric bypass) changes natural body chemicals called 'gut hormones'. We want to see if these changes help people with obesity and type 2 diabetes by burning more energy, eating less, losing weight, and changing how they react to food.
United Kingdom - recruiting
Nottingham Community Liver Biomarkers Cohort
This study in Nottingham looks at improving how we find liver disease early in the community. It involves people with risk factors like heavy alcohol use, obesity, or diabetes, to see if new blood and scan tests can help identify liver problems before they become serious.
United Kingdom - not yet recruitingNA
Effects of HIIT Following PTR Programme
This study looks at whether a home-based exercise program (HIIT) can help people who have put their Type 2 diabetes into remission to stay diabetes-free for longer. It compares this special exercise with usual care after completing the NHS Path to Remission program.
United Kingdom - active not recruitingPHASE3
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
This study looks at a new medicine called Retatrutide for people with Type 2 Diabetes and kidney problems. It checks if the medicine improves blood sugar control and is safe, compared to a dummy medicine, for those already on insulin.
United States · Argentina · Brazil - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.
This study is testing a new treatment, RJVA-001, for adults with Type 2 diabetes that isn't well-controlled. It's the first time this treatment is being given to people. Doctors want to see if it's safe, what dose works best, and how it affects blood sugar.
Netherlands - recruitingNA
taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs
This study looks at a new way to help people with newly diagnosed Type 2 diabetes. It compares a special automated insulin device with standard care to see if it can help put diabetes into remission, meaning you might not need medication.
United Kingdom - active not recruitingPHASE4
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
This study looks at a new treatment called tirzepatide for people with type 2 diabetes. It's compared to standard care to see how well it works and if it's safe when started early. The goal is to improve blood sugar control for those with type 2 diabetes.
United States · Argentina · Canada - active not recruitingNA
Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure
This study looks at a new way to find hidden heart failure in people with diabetes who are at higher risk. We're testing if checking a specific blood marker helps doctors discover heart problems earlier, so people can get the right care sooner.
United Kingdom - enrolling by invitation
Sweet Sensing in Type 2 Diabetes
This study looks at how people with type 2 diabetes and prediabetes sense sweetness. We want to understand if changes in taste and brain activity affect sugar cravings. This could help develop new ways to manage blood sugar.
United Kingdom - recruiting
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
This study looks at why people with a type of heart failure called HFpEF, especially those with Type 2 Diabetes, get so unwell. Using special MRI scans and dyes, researchers want to see how their hearts handle calcium and energy, comparing them to healthy volunteers.
United Kingdom - active not recruitingPHASE3
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study looks at a new medicine called cagrilintide for people with overweight or obesity and type 2 diabetes. It aims to see how well cagrilintide helps people lose weight. Participants will receive either the new medicine or a dummy medicine.
United States · Argentina · Canada - recruiting
The European NAFLD Registry
This study aims to understand fatty liver disease (NAFLD) better. Researchers collect information and samples from patients across Europe to find new ways to detect and monitor the disease, especially how it progresses from fatty liver to more serious conditions like fibrosis.
Belgium · Finland · France - ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
This study is looking at how well a new medicine, Tirzepatide, works for adults with type 2 diabetes when they switch from another medicine called Dulaglutide. Researchers want to see if the new medicine helps lower blood sugar and improve other health markers like weight.
Romania · Germany · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participants
This study is looking at a new tablet for type 2 diabetes. It aims to see how different amounts of the medicine, semaglutide, affect its levels in the blood of healthy male volunteers.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Greece · Germany · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBK: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
This study is looking into a new weekly injection called Retatrutide. It's for people with type 2 diabetes who are also overweight or obese. The main goal is to see how well it helps with weight loss compared to a dummy injection (placebo).
Spain · Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of healthy Japanese participants
This study is testing a new medicine, NNC0113-6856, in healthy people, including some of Japanese background. We want to see how safe it is, how well bodies handle it, and what happens to the medicine inside the body after taking different doses.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
This study is looking at a new daily tablet (called ORFORGLIPRON) for adults who are overweight or have obesity and also have type 2 diabetes. It aims to see how well it helps with weight loss and if it's safe compared to a dummy pill.
Czechia · Germany · Greece - ongoing, recruitingTherapeutic confirmatory (Phase III)
A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti diabetic drugs. COMBINE 4
This study looks at a new once-a-week insulin treatment, IcoSema, for people with type 2 diabetes whose blood sugar isn't well controlled by their current medicines. It compares IcoSema to a daily insulin, glargine, to see which is better and safer.
Greece · Italy · Poland - ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
This study is testing a new combination medicine, CagriSema, for people with type 2 diabetes. It's looking at whether this combined medicine is better at controlling blood sugar and helping with weight loss than existing treatments, including its individual components, semaglutide and cagrilintide.
Denmark · Sweden · Slovakia - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.
This study is looking at a new, long-acting insulin for people with type 2 diabetes. Researchers want to see how it works in the body during exercise and when you haven't eaten for a longer time. It's an early-stage study to understand the new insulin better.
Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGV: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Dapagliflozin in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin (ACHIEVE-2)
This study looks at a new drug, orforglipron, for people with type 2 diabetes whose blood sugar isn't well controlled with metformin. It compares orforglipron with an existing drug, dapagliflozin, to see how well they lower blood sugar and if they're safe.
Poland · Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGW: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
This study is looking into a new daily tablet, orforglipron, for adults with type 2 diabetes. We want to see if it's better than a dummy pill at helping control blood sugar when taken with insulin glargine and other diabetes medicines.
Romania - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes
This study is looking at a new once-a-week insulin treatment, called insulin icodec, for people with type 2 diabetes. It's comparing it to a daily insulin, Lantus, to see if the weekly option is safe and works just as well to control blood sugar.
Poland · Spain · Bulgaria - ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes as add on to once-daily basal insulin with or without metformin
This study is looking at a new combination medicine, CagriSema, for people with type 2 diabetes. We want to see how well it helps control blood sugar and manage weight, alongside their usual insulin and other diabetes medicines.
Slovakia - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.
This study looks at how new medicines, CagriSema and its parts (semaglutide and cagrilintide), work in people with type 2 diabetes. Researchers want to understand how these medicines affect the body's use of insulin and sugar.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes inadequately controlled on diet and exercise.
This study is testing a new combination medicine for people with type 2 diabetes who haven't fully managed their blood sugar with diet and exercise. It looks at how well the medicine works to lower blood sugar and help with weight loss over 40 weeks.
Italy · Hungary · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
Spain · Hungary · Poland - ongoing, recruitingTherapeutic use (Phase IV)
Optimization of Albuminuria-Lowering Therapies for Individual Patients with Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial
This study looks at how well different diabetes medicines work together to protect kidneys in people with type 2 diabetes. It also checks how easy it is for people to take part in a study from home using digital tools, like giving urine samples and checking blood pressure.
Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
Romania · Spain · Poland - authorisedTherapeutic use (Phase IV)
A multicenter, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascular complications
This study compares two common diabetes medicines, dapagliflozin and metformin, for people recently diagnosed with type 2 diabetes. We want to see how these medicines affect serious health problems like heart attacks, strokes, kidney issues, and overall health over time.
Sweden - ongoing, recruitingTherapeutic use (Phase IV)
DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes.
This study looks at how different salt levels in your diet affect a type 2 diabetes drug called ertugliflozin (Steglatro) and your blood pressure. We're comparing recommended salt intake with a higher salt diet in people with type 2 diabetes who are overweight or obese.
Netherlands - not yet recruitingNA
A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis
This study looks at a new automated insulin system, Omnipod 5, for people with type 2 diabetes and advanced kidney failure on dialysis. It aims to see if it improves blood sugar control and quality of life compared to usual care.
United Kingdom - recruitingNA
Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS)
This study in Edinburgh looks at how fat in the pancreas affects type 2 diabetes and if losing weight can reverse it. Participants will follow a special diet to lose weight, helping researchers understand how the body changes and improves.
United Kingdom - recruitingNA
GLycaemic Outcomes With Whey Protein in ageING
This study looks at whether whey protein taken before meals can help older adults (75-90) with Type 2 Diabetes manage their blood sugar levels better. Participants will try different doses of whey protein and a harmless dummy powder.
United Kingdom - recruiting
The Sarcopenia Study
This study looks at muscle weakness, called sarcopenia, in people with heart failure. Researchers want to see if different types of heart failure affect how common sarcopenia is, comparing heart failure patients to healthy people and those with type 2 diabetes.
United Kingdom - authorisedTherapeutic use (Phase IV)
EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study
This study looks at different insulin treatments for people with type 2 diabetes who are just starting insulin. It compares a new once-weekly insulin called Icodec with other daily insulins people usually take. The aim is to see how well they work in real life and how easy they are to use.
Germany · Italy - ongoing, recruitingTherapeutic confirmatory (Phase III)
A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5
This 40-week study looks at two different insulin-based treatments for adults with type 2 diabetes that isn't well-controlled. It compares a new once-weekly injection (IcoSema) with an existing daily or twice-daily insulin (Ryzodeg) to see which is more effective and safer.
Poland - authorisedTherapeutic use (Phase IV)
Phase IV open-label clinical trial of the immunogenicity and safety of standard dose trivalent inactivated influenza vaccine (Vaxigrip) in a population of people with obesity
This study is looking at how well the standard flu jab (Vaxigrip) works and how safe it is for people who are obese. It will also look at those with type 2 diabetes. We want to see if their bodies make enough protection against the flu after having the vaccine.
Sweden - recruitingPHASE2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
This study is looking into a new medication, LY3457263, for people with Type 2 Diabetes whose blood sugar levels are still high despite taking other common diabetes medicines like semaglutide or tirzepatide. It will compare the new drug with a dummy treatment (placebo).
United States · Canada · Germany